Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

At the Table: ACR Meets with MedPAC

  |  

The Medicare Payment Advisory Commission (MedPAC) makes recommendations to Congress on Medicare policy including physician payments and patient access issues. These recommendations can directly impact rheumatology care coverage and rheumatologist reimbursement. Representatives of the ACR and partners recently met with new MedPAC Executive Director James E. Mathews, PhD, to discuss appropriate recognition of rheumatology care…

CMS Releases 2018 MIPS Eligibility Tool

  |  

You can now use the updated CMS MIPS Participation Lookup Tool to check on your 2018 eligibility for the Merit-Based Incentive Payment System (MIPS). Enter your National Provider Identifier (NPI) in the tool to find out whether you need to participate during the 2018 performance year. Changes to Low-Volume Threshold To reduce the burden on…

New Compounding Regulations could Adversely Affect Rheumatologists, Patients

  |  

On July 28, 2018, the USP will publish preliminary updates to existing drug compounding standards that could affect whether rheumatologists maintain the ability to mix, combine or otherwise customize medications in office for individual patient use. The ACR, in concert with the American Medical Association (AMA) and others, is working to help ensure rheumatologists can…

Protecting Patient Care on All Fronts: A Conversation with Kent “Kwas” Huston, MD, ACR Government Affairs Committee Member

  |  

Kent “Kwas” Huston, MD, remembers the conversations he had with his father’s rheumatology patients in Kansas City, Mo., when he visited his father’s practice while he was growing up. “They shared what a difference he made for them,” Dr. Huston explains. Dr. Huston also saw firsthand the importance of rheumatology care. His mother was diagnosed…

Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Reuters Staff  |  

NEW YORK (Reuters Health)—Subcutaneous belimumab improves outcomes in anti-dsDNA-positive hypocomplementemic patients with systemic lupus erythematosus (SLE), according to results from a Phase 3 randomized, controlled trial. Intravenous belimumab is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with active, autoantibody-positive SLE who are receiving standard…

Obesity Linked with Disability in RA

Lisa Rapaport  |  

(Reuters Health)—Patients with rheumatoid arthritis (RA) may be more likely to become disabled if they’re obese, a U.S. study suggests. Researchers examined data on more than 25,000 patients with RA. Most were overweight or obese when they joined the study. Those who were severely obese were more likely to report some disability at baseline. Over…

New Study Raises Cardiovascular Questions about Febuxostat for Gout

  |  

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Clinical Remission Should Be Target of JIA Treatment: Task Force

Reuters Staff  |  

NEW YORK (Reuters Health)—An international task force says patients with juvenile idiopathic arthritis (JIA) should be treated to a target of clinical remission, among other new recommendations. “The Task Force is convinced that transferring (the recommendations) into clinical practice will significantly improve the outcomes in patients with JIA,” Dr. Angelo Ravelli of the Istituto G….

New Arthritis Estimates Put Prevalence Numbers Much Higher Than Previously Thought

Catherine Kolonko  |  

  Arthritis is often associated with retirees, but a new analysis of government data suggests the disease is much more common in young and middle-aged adults than previously believed. Disease prevalence is currently estimated at about 54 million adults, but that number is greatly underestimated, especially among those 64 and younger, according to a study…